Ascendis Pharma A/SNASDAQ:ASND
- LAST PRICE127.7100
- TODAY'S CHANGE (%)-0.6900 (-0.5374%)
- Bid / Lots127.1300/ 8
- Ask / Lots128.1100/ 8
- Open / Previous Close127.3900 / 128.4000
- Day Range
- 52 Week Range
- Volume251,295
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ASND |
|---|---|---|
| 09:32 ET | 1277 | 126.415 |
| 09:33 ET | 1891 | 126.92 |
| 09:35 ET | 200 | 127.13 |
| 09:37 ET | 206 | 127.7606 |
| 09:39 ET | 400 | 127.8 |
| 09:42 ET | 400 | 127.1 |
| 09:44 ET | 1800 | 127.22 |
| 09:46 ET | 300 | 127.86 |
| 09:48 ET | 2458 | 127.75 |
| 09:50 ET | 2580 | 127.9 |
| 09:51 ET | 2316 | 127.4 |
| 09:53 ET | 600 | 127.64 |
| 09:57 ET | 100 | 127.565 |
| 10:00 ET | 2200 | 127.4 |
| 10:02 ET | 300 | 127.54 |
| 10:04 ET | 1100 | 127.385 |
| 10:06 ET | 3267 | 127.03 |
| 10:08 ET | 2940 | 126.49 |
| 10:09 ET | 100 | 126.48 |
| 10:11 ET | 3300 | 126.9125 |
| 10:13 ET | 400 | 126.91 |
| 10:15 ET | 600 | 127.01 |
| 10:18 ET | 700 | 127.1805 |
| 10:20 ET | 922 | 128.1 |
| 10:26 ET | 3541 | 127.38 |
| 10:27 ET | 469 | 127.685 |
| 10:29 ET | 300 | 127.705 |
| 10:31 ET | 300 | 127.375 |
| 10:33 ET | 1813 | 127.73 |
| 10:36 ET | 100 | 127.36 |
| 10:38 ET | 748 | 127.36 |
| 10:40 ET | 5323 | 127.45 |
| 10:42 ET | 2923 | 127.32 |
| 10:44 ET | 200 | 127.45 |
| 10:45 ET | 300 | 127.335 |
| 10:47 ET | 606 | 127.33 |
| 10:49 ET | 500 | 127.35 |
| 10:51 ET | 769 | 127.72 |
| 10:54 ET | 1067 | 127.75 |
| 10:56 ET | 891 | 127.56 |
| 10:58 ET | 400 | 127.73 |
| 11:00 ET | 200 | 127.63 |
| 11:02 ET | 200 | 127.38 |
| 11:03 ET | 329 | 127.775 |
| 11:05 ET | 100 | 127.76 |
| 11:07 ET | 500 | 127.73 |
| 11:09 ET | 300 | 127.64 |
| 11:12 ET | 640 | 127.67 |
| 11:14 ET | 1000 | 127.555 |
| 11:16 ET | 200 | 127.68 |
| 11:18 ET | 1405 | 127.555 |
| 11:20 ET | 6004 | 127.635 |
| 11:21 ET | 3844 | 127.7999 |
| 11:23 ET | 1400 | 127.9 |
| 11:25 ET | 1925 | 128.685 |
| 11:30 ET | 1744 | 128.63 |
| 11:32 ET | 700 | 128.36 |
| 11:34 ET | 1322 | 128.755 |
| 11:36 ET | 300 | 129.05 |
| 11:38 ET | 100 | 128.78 |
| 11:39 ET | 200 | 128.91 |
| 11:41 ET | 200 | 128.94 |
| 11:43 ET | 400 | 128.87 |
| 11:45 ET | 100 | 128.85 |
| 11:48 ET | 300 | 128.675 |
| 11:50 ET | 100 | 128.84 |
| 11:52 ET | 346 | 128.76 |
| 11:54 ET | 300 | 128.8 |
| 11:56 ET | 3406 | 129.26 |
| 11:57 ET | 2825 | 128.45 |
| 11:59 ET | 335 | 128.49 |
| 12:01 ET | 1415 | 128.58 |
| 12:06 ET | 200 | 128.485 |
| 12:08 ET | 1971 | 127.075 |
| 12:10 ET | 1108 | 127.32 |
| 12:12 ET | 194 | 127.34 |
| 12:14 ET | 100 | 127.34 |
| 12:15 ET | 500 | 127.44 |
| 12:17 ET | 274 | 127.385 |
| 12:19 ET | 842 | 127.41 |
| 12:21 ET | 100 | 127.41 |
| 12:24 ET | 225 | 127.41 |
| 12:26 ET | 300 | 127.485 |
| 12:28 ET | 600 | 127.45 |
| 12:30 ET | 2800 | 127.985 |
| 12:35 ET | 1100 | 128.195 |
| 12:37 ET | 400 | 128.32 |
| 12:39 ET | 498 | 128.36 |
| 12:42 ET | 325 | 128.085 |
| 12:44 ET | 300 | 128.14 |
| 12:46 ET | 500 | 128.13 |
| 12:48 ET | 900 | 128.125 |
| 12:50 ET | 4656 | 128.29 |
| 12:51 ET | 100 | 128.19 |
| 12:53 ET | 1675 | 128.3 |
| 12:55 ET | 1000 | 128.26 |
| 12:57 ET | 2041 | 128.42 |
| 01:00 ET | 500 | 128.34 |
| 01:02 ET | 700 | 128.49 |
| 01:04 ET | 864 | 128.47 |
| 01:06 ET | 4047 | 128.66 |
| 01:08 ET | 270 | 129.02 |
| 01:09 ET | 400 | 129.08 |
| 01:11 ET | 1100 | 128.98 |
| 01:13 ET | 800 | 128.94 |
| 01:15 ET | 4409 | 128.45 |
| 01:18 ET | 894 | 128.69 |
| 01:20 ET | 1000 | 128.59 |
| 01:22 ET | 1000 | 128.78 |
| 01:24 ET | 5787 | 128.8764 |
| 01:26 ET | 39784 | 127.18 |
| 01:27 ET | 5888 | 128.285 |
| 01:29 ET | 4991 | 129.19 |
| 01:31 ET | 900 | 128.92 |
| 01:33 ET | 200 | 128.795 |
| 01:36 ET | 1455 | 128.44 |
| 01:38 ET | 400 | 128.4 |
| 01:40 ET | 312 | 128.39 |
| 01:44 ET | 200 | 128 |
| 01:45 ET | 600 | 127.62 |
| 01:47 ET | 100 | 127.71 |
Nov 7, 2024
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 4, 2024
DJ Ascendis Pharma Price Target Maintained With a $170.00/Share by Cantor Fitzgerald, from 8:53AM ET on Monday Nov 04, 2024 by Dow Jones
8:53AM ET on Monday Nov 04, 2024 by Dow JonesAscendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 23, 2024
DJ Ascendis Pharma Is Maintained at Overweight by JP Morgan, from 8:00AM ET on Wednesday Oct 23, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 23, 2024 by Dow Jones
Oct 21, 2024
DJ Ascendis Pharma Is Maintained at Buy by TD Cowen, from 1:25PM ET on Monday Oct 21, 2024 by Dow Jones
1:25PM ET on Monday Oct 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ascendis Pharma A/S | 7.8B | -13.9x | --- |
Legend Biotech Corp | 7.4B | -25.5x | --- |
Blueprint Medicines Corp | 6.3B | -46.4x | --- |
Intra-Cellular Therapies Inc | 9.7B | -104.1x | --- |
Madrigal Pharmaceuticals Inc | 7.4B | -13.4x | --- |
Viking Therapeutics Inc | 7.0B | -62.1x | --- |
Company Information
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Contact Information
- Headquarters
- Tuborg Boulevard 12HELLERUP, Denmark 2900
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Albert Cha
- President, Chief Executive Officer, Executive Director, Member of the Executive Board
- Jan Moller Mikkelsen
- Chief Financial Officer, Executive Vice President, Member of the Executive Board
- Scott Smith
- Executive Vice President, Chief Administrative Officer
- Lotte Soenderbjerg
- Executive Vice President, Global Chief Commercial Officer
- Camilla Hartvig
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.8B |
|---|---|
Revenue (TTM) | $338.4M |
Shares Outstanding | 60.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.65 |
EPS | $-9.19 |
Book Value | $-2.69 |
P/E Ratio | -13.9x |
Price/Sales (TTM) | 23.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -111.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
